Mesothelin-Directed Bispecific Antibodies for Mesothelioma

Mesothelin-directed bispecific antibodies are an investigational class of cancer immunotherapy being studied in mesothelioma. They are laboratory-engineered antibodies with two binding arms: one arm grips mesothelin, a protein overexpressed on the surface of mesothelioma cells, and the other grips CD3, a signaling molecule on the patient's own T cells. By physically bridging the two, the antibody redirects T cells to attack mesothelin-positive tumor cells. This makes them a third mesothelin-targeting modality, distinct from mesothelin CAR-T therapy and from antibody-drug conjugates. As of 2026 no mesothelin-directed bispecific antibody is approved by the U.S. Food and Drug Administration for mesothelioma or any other indication; the modality is being evaluated only in early-phase clinical trials.

Executive Summary

Mesothelin-directed bispecific antibodies represent an emerging, off-the-shelf approach to engaging the immune system against mesothelioma. Unlike CAR-T therapy, they require no collection or genetic engineering of a patient's own cells — they are manufactured antibodies given as a drug. The lead agent, JNJ-79032421, was engineered specifically to overcome the "shed-antigen sink," a long-standing obstacle for mesothelin-targeted drugs. Two Phase 1 trials define the current clinical landscape: JNJ-79032421 (NCT06255665, sponsor Janssen), which has Completed its Phase 1 study with no efficacy results yet published, and CT-95 (NCT06756035, sponsor Context Therapeutics), which is Recruiting in a basket that includes pleural and peritoneal mesothelioma. This page describes the mechanism and trial landscape only; no efficacy or response-rate data have been reported for either agent.

At a Glance

• What it is: An engineered antibody with two arms — one binds mesothelin on the tumor, the other binds CD3 on a T cell — redirecting T cells to kill mesothelin-positive cancer cells.
• How it differs from CAR-T: Off-the-shelf drug; no patient cell collection, no genetic engineering of T cells, no manufacturing wait per patient.
• Lead agent: JNJ-79032421 (Janssen), designed to bind only the non-shed, membrane-anchored stub of mesothelin.
• Trial status: JNJ-79032421 Phase 1 — Completed (no efficacy readout published). CT-95 Phase 1 — Recruiting.
• Approval status: No mesothelin-directed bispecific antibody is FDA-approved for any indication as of 2026.
• Evidence base: One peer-reviewed preclinical characterization plus two early-phase clinical-trial registry records. No patient efficacy data reported.

Key Facts

Attribute	Detail
Modality	T-cell-engaging (CD3) bispecific antibody targeting mesothelin
Lead agent	JNJ-79032421 (mesothelin × CD3)
Second agent	CT-95 (mesothelin × CD3)
JNJ-79032421 trial	NCT06255665, Phase 1, Completed, sponsor Janssen Research & Development, enrollment 35
CT-95 trial	NCT06756035, Phase 1, Recruiting, sponsor Context Therapeutics, enrollment 70
Mechanism paper	Smans K, et al. Mol Cancer Ther 2026 (PMID 41773493)
FDA status	Not approved for any indication (investigational)
Efficacy data	None published for either agent as of 2026

What Are Mesothelin-Directed Bispecific Antibodies?

A bispecific antibody is a single molecule engineered to bind two different targets at once. In the T-cell-engaging (TCE) format used against mesothelioma, one binding arm attaches to mesothelin — a cell-membrane glycoprotein overexpressed in mesothelioma, pancreatic cancer, and ovarian cancer — while the other arm attaches to CD3, part of the T-cell receptor complex on the patient's own T cells. By holding a T cell and a tumor cell in close proximity, the antibody triggers the T cell to release its cytotoxic payload against the tumor cell, independent of the T cell's own antigen specificity.

This mechanism places bispecific antibodies alongside — but distinct from — the two other mesothelin-targeting strategies studied in mesothelioma. Mesothelin CAR-T therapy removes a patient's T cells, genetically engineers them to recognize mesothelin, and reinfuses them. Antibody-drug conjugates instead deliver a chemotherapy payload directly to mesothelin-bearing cells. A T-cell-engaging bispecific is an "off-the-shelf" drug: it is manufactured in advance, requires no collection or engineering of a patient's own cells, and is administered like other antibody therapies. Because it recruits the patient's existing T cells rather than a manufactured cell product, it avoids the per-patient cell-manufacturing step that CAR-T requires. All mesothelin-directed bispecific antibodies remain investigational; none is FDA-approved.

The Shed-Antigen Problem and the JNJ-79032421 Design

Mesothelin has long frustrated drug developers because of a biological quirk. The protein is cleaved by proteases near the cell membrane, which releases a soluble fragment — shed mesothelin (sMSLN) — into the tumor microenvironment while leaving a short, membrane-bound stub on the cell surface. Circulating shed mesothelin is hypothesized to act as a "sink" or decoy: a mesothelin-targeting drug can be soaked up by the free-floating fragment before it ever reaches the tumor cell, blunting the therapy.

JNJ-79032421 was engineered specifically to defeat this problem. According to its preclinical characterization, the antibody was designed to bind only the membrane-restricted, non-shed C-terminal stub of mesothelin — the portion that stays attached to the tumor cell after cleavage — rather than the shed fragment that floats away. In principle, this membrane-restricted design means the drug is not neutralized by the shed-antigen sink and engages T cells only at the tumor-cell surface. This reframes shed-antigen escape from a dead end into an engineering constraint that a next-generation molecule can be built around. This characterization is preclinical; whether the design translates into patient benefit has not been reported.

Where the Trials Stand: JNJ-79032421 and CT-95

Two Phase 1 clinical trials define the current landscape for mesothelin-directed bispecific antibodies. Both are early-phase, first-in-class dose-finding studies, and neither has published efficacy results.

JNJ-79032421 (NCT06255665). This first-in-human Phase 1 study, sponsored by Janssen Research & Development, evaluated JNJ-79032421 as a T-cell-redirecting agent targeting mesothelin in advanced solid tumors. Its registry status is Completed; the study enrolled 35 participants, began on February 9, 2024, and reached primary completion on June 23, 2025. "Completed" indicates the trial finished its planned course — it does not mean the drug was shown to be effective. As of 2026 no efficacy or response-rate results have been posted to the trial registry or published.

CT-95 (NCT06756035). CT-95 is a separate mesothelin × CD3 bispecific antibody developed by Context Therapeutics. Its Phase 1a/1b study is evaluating CT-95 in advanced cancers associated with mesothelin expression, a "basket" design whose eligible conditions include advanced pleural and peritoneal mesothelioma. The registry status is Recruiting, with a planned enrollment of 70 and a start date of March 31, 2025. Because this is a Phase 1 dose-finding trial, participation is restricted by strict eligibility criteria; "Recruiting" means the trial is enrolling qualifying patients at its study sites, not that the drug is broadly available. Patients interested in trial participation should discuss eligibility with their treating oncologist and can review a mesothelioma legal and medical resource such as Danziger & De Llano alongside their care team.

How This Differs From Mesothelin CAR-T Therapy

Mesothelin-directed bispecific antibodies and mesothelin CAR-T therapy both aim T cells at the same tumor protein, but they are fundamentally different products. CAR-T therapy is a living cell product: a patient's own T cells are collected, genetically reprogrammed in a laboratory to express a chimeric antigen receptor against mesothelin, expanded, and reinfused — a bespoke, per-patient manufacturing process that takes time and specialized facilities. A bispecific antibody is an off-the-shelf drug: it is produced in advance, stored, and given to any eligible patient without collecting or engineering that patient's cells.

The practical distinctions matter for patients weighing where the field is headed. Bispecifics avoid the manufacturing delay and complexity of CAR-T but must be dosed repeatedly like other antibody drugs, whereas an infused CAR-T product is designed to persist and expand in the body. Both approaches remain investigational in mesothelioma. This page covers the bispecific-antibody modality only; for the distinct CAR-T approach see the dedicated mesothelin CAR-T therapy page, and for the broader treatment context see mesothelioma immunotherapy.

Frequently Asked Questions

What is a bispecific antibody?

A bispecific antibody is a single engineered molecule with two different binding arms. In mesothelioma research, one arm binds mesothelin on the tumor cell and the other binds CD3 on a T cell, physically bridging the two so the T cell attacks the tumor cell. Unlike a natural antibody, which binds one target, a bispecific is designed to connect two — turning the patient's own T cells into anti-tumor effectors without genetically modifying them.

Are mesothelin bispecific antibodies available for mesothelioma patients now?

No. As of 2026, no mesothelin-directed bispecific antibody is approved by the FDA for mesothelioma or any other cancer. They are being studied only in early-phase clinical trials — JNJ-79032421 (Phase 1, Completed) and CT-95 (Phase 1, Recruiting). Access is limited to patients who qualify for and enroll in an open trial.

How is a bispecific antibody different from CAR-T therapy?

CAR-T therapy engineers a patient's own T cells in a lab and reinfuses them — a living, per-patient cell product. A bispecific antibody is an off-the-shelf drug, manufactured in advance and given like other antibody infusions, that recruits a patient's existing T cells without collecting or genetically modifying them. Both target mesothelin but differ in how the T cells are engaged.

When might efficacy results be published?

No efficacy or response-rate data have been reported for JNJ-79032421 or CT-95 as of 2026. The JNJ-79032421 Phase 1 trial reached primary completion in June 2025, so results may appear in a future publication or registry update, while CT-95 is still recruiting. Patients and families should rely on peer-reviewed publications and official trial-registry updates rather than preliminary or promotional claims.

See Also

• Mesothelin CAR-T Therapy Mesothelioma — the CAR-T cell-therapy approach to the same tumor target
• Mesothelioma Immunotherapy — the broader immunotherapy landscape, including checkpoint inhibitors